MapLight Therapeutics, Inc. Form 4 Filings

MapLight Therapeutics, Inc. (MPLT) reported that Chief Discovery Officer Anatol Kreitzer received equity awards on August 17, 2026. He was granted an option to purchase 24,455 shares of voting common stock at an exercise price of $11.245 per share, expiring August 16, 2036; 1/4 of the option vests on July 1, 2027 and 1/48 vests monthly thereafter, subject to continued service. He also received 6,020 RSUs, with 1/4 vesting on July 1, 2027 and 1/16 vesting on each subsequent October 1, January 1, April 1, and July 1, subject to continued service. Following these grants, he directly holds 180,926 shares of common stock.

MapLight Therapeutics, Inc. (MPLT) reported equity awards to its CAO and Interim CFO, Jonathan Gillis. On August 17, 2026 he received two stock option grants to purchase a total of 27,268 shares of voting common stock at an exercise price of $11.245 per share, expiring on August 16, 2036, with vesting in quarterly or monthly installments subject to continued service. He also received two restricted stock unit awards totaling 8,242 RSUs, each RSU representing one share of voting common stock, vesting over multi-year quarterly schedules, also contingent on continued service.

MapLight Therapeutics, Inc. (MPLT) reported that its Chief Scientific Officer, Lillie James Woodruff, received equity awards on August 17, 2026. She was granted an employee stock option covering 31,395 shares of voting common stock at an exercise price of $11.245 per share, expiring on August 16, 2036. According to the vesting terms, one quarter of the option shares vest on July 1, 2027, with 1/48th of the total shares vesting monthly thereafter, subject to her continued service.

On the same date she also received a restricted stock unit award covering 7,730 shares of voting common stock, with each RSU representing a contingent right to receive one share upon vesting. One quarter of these RSUs vest on July 1, 2027, and 1/16th vest on each subsequent October 1, January 1, April 1 and July 1, subject to continued service. Following this RSU grant, her direct holdings of voting common stock increased to 210,110 shares.

MapLight Therapeutics, Inc. (MPLT) reported that its General Counsel, Kristopher Hanson, received equity awards on August 17, 2026. He was granted 31,395 stock options with an exercise price of $11.245 per share, expiring August 16, 2036, and a separate award of 7,730 restricted stock units (RSUs). The options and RSUs vest over time, beginning July 1, 2027, subject to his continued service, and his direct voting common stock holdings increased to 153,553 shares after the RSU grant.

MapLight Therapeutics, Inc. (MPLT) reported equity compensation awards to its Chief Medical Officer, Erin Pennock Foff. She received an option for 54,240 shares of voting common stock at an exercise price of $11.245 per share, expiring on August 16, 2036, and a restricted stock unit award covering 13,360 shares. Both awards vest over time subject to continued service, and following these grants she directly holds 312,261 shares of voting common stock.

MapLight Therapeutics, Inc. (MPLT) reported that its Chief Executive Officer and director, Christopher A. Kroeger, received equity awards on August 17, 2026. He was granted an option to purchase 93,955 shares of voting common stock at an exercise price of $11.245 per share, expiring August 16, 2036; one quarter of these option shares vest on July 1, 2027, and the rest in equal monthly installments thereafter, subject to continued service. He also received 23,145 restricted stock units, each representing one share of voting common stock, with one quarter vesting on July 1, 2027 and the remainder in equal quarterly installments, also subject to continued service. Following these awards he directly holds 1,269,600 shares of voting common stock, and an additional 101,190 shares are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse serve as co-trustees with voting and dispositive power.

MapLight Therapeutics, Inc. (MPLT) reported that 10% owner Catalyst4, Inc. purchased 4,400,000 shares of Voting Common Stock and warrants for 2,928,686 shares on August 14, 2026 at around $11.38 per share. The warrants are immediately exercisable at $0.0001 per share but include a 49.99% beneficial ownership cap and do not expire until exercised in full. After these purchases, Catalyst4 indirectly holds 25,306,689 shares of Voting Common Stock, with voting and dispositive power shared by its directors, who each disclaim beneficial ownership.

Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics, Inc., reported selling 22,082 shares of Voting Common Stock on August 3, 2026 at a weighted average price of $12.54 per share, in transactions ranging from $12.12 to $12.99, pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025. Following this sale, Woodruff directly holds 202,380 shares of the company’s common stock.

Catalyst4, Inc., reported as a 10% owner of MapLight Therapeutics, Inc., purchased a total of 1,209,225 shares of Voting Common Stock in open market or private transactions from July 28–30, 2026. The purchases included 1,000,000 shares at $13.0000 per share and additional shares at $12.6300 and weighted-average prices within ranges of $10.295–$11.28 and $11.31–$12.00 per share. The shares are held of record by Catalyst4, whose board members share voting and dispositive power and each disclaims beneficial ownership; the trades were not marked as made under a Rule 10b5-1 trading plan.

MapLight Therapeutics, Inc. director Troy Cox, through a revocable trust, purchased 15,620 shares of Voting Common Stock on July 28, 2026 at a weighted-average price of $9.5200 per share, with individual trade prices ranging from $9.305 to $9.78.

After this purchase, the trust holds 15,620 shares, and Cox also directly owns 7,864 shares of MapLight Therapeutics Voting Common Stock.

MapLight Therapeutics, Inc. executive Jonathan Gillis, CAO and Interim CFO, reported selling 36,979 shares of Voting Common Stock from July 15–17, 2026 in seven Code S transactions at weighted-average prices ranging from $35.68 to $38.37 per share.

Certain July 15–16 sales are described as mandated “sell to cover” trades to satisfy statutory tax withholding obligations upon restricted stock unit vesting, while the July 17 sales were executed under a Rule 10b5-1 trading plan adopted on December 26, 2025. After one July 17 sale, the table shows 144,240 shares held directly.

MapLight Therapeutics, Inc. reporting person Anatol Kreitzer, Chief Discovery Officer, reported selling 36,284 shares of Voting Common Stock from July 15–17, 2026 at weighted-average prices, with underlying trade prices ranging from $35.68 to $38.21 per share. Sales on July 15–16 covered statutory tax withholding from vesting restricted stock units via mandated “sell to cover” transactions, while July 17 sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. Following these transactions, Kreitzer directly held 174,906 shares of Voting Common Stock.

MapLight Therapeutics, Inc. CEO and director Christopher A. Kroeger reported sales totaling 147,639 shares of Voting Common Stock between July 15 and 17, 2026. Footnotes state these were mandated sell‑to‑cover transactions to satisfy statutory tax withholding on vested restricted stock units, rather than discretionary sales. After these transactions, he holds 1,246,455 shares directly and 101,190 shares indirectly through the C&M Kroeger Nominee Trust, over which he has voting and dispositive power.

MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff reported selling 18,267 shares of Voting Common Stock from July 15–17, 2026, at prices between $35.5338 and $37.925 per share. The disclosure states these mandated sell to cover transactions satisfied statutory tax withholding on vested restricted stock units, leaving her with 224,462 shares held directly.

MapLight Therapeutics, Inc. General Counsel Kristopher Hanson reported sales totaling 16,508 shares of Voting Common Stock between July 15 and 17, 2026. These shares were sold to cover statutory tax withholding obligations arising from vesting restricted stock units, and he now directly holds 145,823 shares.

MapLight Therapeutics, Inc. reported that Chief Medical Officer Erin Pennock Foff sold a total of 47,158 shares of Voting Common Stock over July 15–17, 2026. After these transactions, she directly holds 298,901 shares. Certain sales were executed under a Rule 10b5-1 trading plan adopted on December 29, 2025, while others were mandated "sell to cover" transactions to satisfy statutory tax withholding arising from vesting restricted stock units.

MapLight Therapeutics director Troy Cox received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units, each representing one share of voting common stock. These RSUs vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service.

He was also granted a stock option covering 29,804 shares of voting common stock at an exercise price of $28.64 per share, vesting on the same three-year schedule starting June 23, 2027. After these grants, his reported direct holdings include 7,864 shares from RSUs and 29,804 underlying option shares.

MapLight Therapeutics director Babler Martin received new equity awards as part of non-employee director compensation. He was granted 7,864 restricted stock units and a stock option for 29,804 shares of Voting Common Stock at an exercise price of $28.64 per share.

The RSUs and option were granted under the 2025 Equity Incentive Plan and will vest in three equal annual installments beginning on June 23, 2027, contingent on his continued service. Following these grants, Martin holds 7,864 shares of Voting Common Stock directly and the newly granted option covering 29,804 underlying shares.

MapLight Therapeutics director Timothy John Garnett received new equity awards as part of non-employee director compensation. He was granted 3,932 restricted stock units, each representing one share of voting common stock, and a stock option for 14,902 shares at an exercise price of $28.64 per share.

Both the RSUs and the option vest on the earlier of June 23, 2027 or the company’s next annual stockholder meeting, subject to his Continuous Service under the 2025 Equity Incentive Plan. Following these awards, he holds 53,457 shares directly and 14,124 shares indirectly through the Timothy J Garnett Revocable Trust, where he has voting and dispositive power.

MapLight Therapeutics, Inc. reported that director Nanna Liebach Luneborg received new equity awards as part of non-employee director compensation. She was granted 3,932 restricted stock units, each representing one share of voting common stock, and a stock option for 14,902 shares at an exercise price of $28.64 per share.

Both the RSUs and the option were granted under the company’s 2025 Equity Incentive Plan and will vest on the earlier of June 23, 2027, or the date of the next annual stockholder meeting, subject to her continuous service.

MapLight Therapeutics director George Pavlov received new equity compensation. He was granted 3,932 restricted stock units (RSUs), each representing one share of voting common stock, under the company’s 2025 Equity Incentive Plan. After this award, he directly holds 28,932 shares of voting common stock.

He was also granted a stock option covering 14,902 shares of voting common stock at an exercise price of $28.64 per share, expiring on June 22, 2036. Both the RSUs and the option vest on the earlier of June 23, 2027, or the date of MapLight’s next annual stockholder meeting, subject to his Continuous Service under the non-employee director compensation policy.

MapLight Therapeutics director Maria C. Walker received new equity awards as part of non-employee director compensation. She was granted 3,932 restricted stock units, each representing one share of voting common stock. These RSUs vest on the earlier of June 23, 2027 or the company’s next annual stockholder meeting, subject to her continuous service.

Walker also received a stock option for 14,902 shares of voting common stock at an exercise price of $28.64 per share, expiring on June 22, 2036, with the same vesting schedule. After the RSU grant, her direct holdings of voting common stock total 62,703 shares. These are compensation-related awards rather than open-market purchases.

MapLight Therapeutics, Inc. Chief Executive Officer Christopher A. Kroeger reported open-market sales of Voting Common Stock. He sold a total of 118,235 shares on May 18, 2026 across two transactions at weighted average prices of $27.19 and $28.15 per share.

These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025. Following the sales, Kroeger directly holds 1,394,094 shares of Voting Common Stock, indicating he retains a substantial equity stake in the company.

MapLight Therapeutics, Inc. General Counsel Kristopher Hanson reported open-market sales of 13,917 shares of Voting Common Stock on May 11, 2026 under a pre-arranged Rule 10b5-1 trading plan. The trades were executed in four tranches at weighted average prices between $27.61 and $30.56 per share.

After these transactions, Hanson directly holds 162,331 shares of MapLight Therapeutics. The filing notes that each reported price is a weighted average of multiple trades within disclosed price ranges, and Hanson has agreed to provide detailed breakdowns of individual sale prices upon request.

MapLight Therapeutics, Inc. Chief Executive Officer Christopher A. Kroeger reported multiple open-market sales of Voting Common Stock. Across several trades on May 7–11, 2026, he sold a total of 68,491 shares, according to the transaction summary.

The sales were executed at weighted average prices within reported ranges from about $27.11 to $30.90 per share, with detailed ranges provided for each trade. A footnote states these transactions were carried out under a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre-arranged rather than timed discretionarily.

MapLight Therapeutics, Inc. Chief Medical Officer Erin Pennock Foff reported open-market sales of a total of 4,438 shares of Voting Common Stock on May 7, 2026. The trades, executed at weighted average prices around $28–$29 per share, were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were scheduled in advance rather than timed discretionarily.

MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff reported an open-market sale of 721 shares of Voting Common Stock on May 7, 2026 at a weighted average price of $28.28 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025, indicating it was scheduled in advance. After this transaction, Woodruff directly holds 242,729 shares of the company’s stock. The filing notes that the shares were sold in multiple trades at prices between $28.08 and $28.90 per share.

MapLight Therapeutics, Inc. Chief Financial Officer Vishwas Setia reported open-market sales of a total of 36,371 shares of Voting Common Stock over May 4–6, 2026. The trades were executed at weighted average prices reported between about $26.84 and $30.55 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 29, 2025. Following these transactions, Setia directly owns 356,256 shares of MapLight Therapeutics common stock.

MapLight Therapeutics Chief Medical Officer Erin Pennock Foff sold 50,280 shares of Voting Common Stock in open-market trades. The sales occurred on May 4–6, 2026 at prices generally in the high‑$20s to low‑$30s per share.

The transactions were made under a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre‑scheduled. After these sales, Foff directly holds 350,497 shares of MapLight Therapeutics common stock.

MapLight Therapeutics, Inc. Chief Scientific Officer Lillie James Woodruff sold 51,707 shares of Voting Common Stock in open‑market transactions. The sales occurred on May 4–6, 2026 at prices reported around the high‑$20s to low‑$30s per share, with some trades executed at weighted average prices.

After these transactions, Woodruff directly holds 243,450 shares of Voting Common Stock. The filing states that the trades were made pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025, indicating they were pre‑scheduled rather than discretionary market‑timed sales.

MapLight Therapeutics General Counsel Kristopher Hanson reported selling 13,917 shares of Voting Common Stock in open‑market trades. The sales occurred on May 4, 2026 at weighted average prices, with individual trades ranging from $26.84 to $30.55 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on December 29, 2025. After the sales, Hanson directly holds 176,248 shares.

MapLight Therapeutics, Inc. director and CEO Christopher A. Kroeger reported open‑market sales of Voting Common Stock. Over May 4–6, 2026, he sold a total of 49,744 shares in multiple transactions classified as open‑market sales under code S, at prices reported as weighted averages.

The filing shows these transactions were executed pursuant to a Rule 10b5‑1 trading plan adopted on December 29, 2025, meaning they were pre‑scheduled. After the reported sales, Kroeger directly holds 1,580,820 shares of Voting Common Stock and an additional 101,190 shares are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse have voting and dispositive power.

MapLight Therapeutics CAAO and PAO Jonathan Gillis reported open-market sales of 69,835 shares of Voting Common Stock. The transactions occurred on April 27–28, 2026, across five sales at weighted average prices such as $28.94 and $30.83 per share. All sales were executed under a Rule 10b5-1 trading plan adopted on December 26, 2025, and he continues to hold a direct equity position reported in the filing.

MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer sold 45,422 shares of Voting Common Stock in open-market transactions. The sales occurred on April 27, 2026 at weighted average prices of $28.96, $29.63, and $30.50 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Kreitzer directly held 211,190 shares of MapLight Therapeutics common stock.

MapLight Therapeutics Chief Discovery Officer Anatol Kreitzer reported a routine share sale linked to tax withholding. On April 15, 2026, he sold 3,316 shares of Voting Common Stock at a weighted average price of $26.61 per share to cover statutory tax obligations from vesting restricted stock units, and now holds 256,612 shares directly.

MapLight Therapeutics officer Jonathan Gillis, CAAO and PAO, sold 3,590 shares of Voting Common Stock in an open-market transaction at a weighted average price of $26.61 per share. According to the footnotes, these shares were sold solely to cover statutory tax withholding obligations tied to the vesting of restricted stock units.

After the sale, Gillis directly owned 251,054 shares, which includes 121 shares acquired under the company’s stock purchase plan on March 31, 2026. The sale price range for the transaction was between $26.6045 and $26.6093 per share.

MapLight Therapeutics General Counsel Kristopher Hanson reported small open‑market sales of Voting Common Stock primarily to cover taxes on vesting stock awards. He sold a total of 1,827 shares across three transactions at prices around $26.80, $27.01, and $27.49 per share, as described with weighted average price ranges in the footnotes.

A footnote states the transactions represent shares sold to satisfy statutory tax withholding obligations tied to restricted stock unit vesting, indicating these are mechanistic rather than discretionary sales. After these transactions and prior plan purchases, Hanson directly holds 190,165 shares of MapLight Therapeutics common stock.

MapLight Therapeutics Chief Financial Officer Vishwas Setia reported open-market sales of Voting Common Stock primarily to cover taxes on restricted stock unit vesting. Across three transactions on April 15–16, he sold a total of 2,922 shares at weighted average prices around $26.87–$27.49. The sales included shares required to satisfy statutory tax withholding obligations. After these transactions, he directly owned 392,627 shares of Voting Common Stock, indicating he retained the vast majority of his equity position.

MapLight Therapeutics Chief Scientific Officer Lillie James Woodruff sold 4,513 shares of Voting Common Stock primarily to cover tax obligations from vested restricted stock units. The sales occurred on April 15–16, 2026 at weighted average prices around $26–27 per share.

After these transactions, she directly holds 295,157 shares. A footnote explains that the shares sold represent the number required to satisfy statutory tax withholding tied to RSU vesting, indicating a compensation-related, rather than purely discretionary, reduction in her holdings.

MapLight Therapeutics, Inc. Chief Medical Officer Erin Pennock Foff reported open-market sales of 3,213 shares of Voting Common Stock on April 15–16, 2026. The filing notes these shares were required to be sold to cover statutory tax withholding obligations tied to vested restricted stock units, making the activity largely mechanistic rather than discretionary. Reported weighted average sale prices ranged from about $26.84 to $27.49 per share. Following the transactions, Foff directly holds 400,777 shares, which includes 155 shares acquired under the company’s stock purchase plan on March 31, 2026.

MapLight Therapeutics, Inc. director and CEO Christopher A. Kroeger reported stock sales primarily tied to tax withholding. On April 15–16, he disposed of a total of 19,187 shares of Voting Common Stock at weighted average prices in the $26–$28 range. A footnote states these sales represent shares required to cover statutory tax withholding obligations related to vesting restricted stock units, indicating they are compensation-driven rather than discretionary portfolio moves. After these transactions, Kroeger holds 1,630,564 shares directly and 101,190 shares indirectly through the C&M Kroeger Nominee Trust, where he has voting and dispositive power.

MapLight Therapeutics director Robert C. Malenka sold 8,593 shares of Voting Common Stock on April 15, 2026 in an open-market transaction at a weighted average price of $26.90 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025.

After the sale, Malenka held 316,466 shares directly, and a separate filing line shows 31,672 shares held indirectly through the Robert C. Malenka Living Trust, where he is sole trustee with voting and dispositive power. The reported sales occurred in multiple trades between $26.35 and $27.29 per share.

MapLight Therapeutics director Robert C. Malenka reported open‑market sales of 14,195 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements. The shares were sold between $18.00 and $19.15 per share across transactions on February 20–24, 2026, leaving him with 325,059 shares held directly. An additional 31,672 shares are held indirectly through the Robert C. Malenka Living Trust, for which he serves as sole trustee with voting and dispositive power, and these retained securities remain subject to a 180‑day IPO lock‑up agreement following the final prospectus dated October 26, 2025.

MapLight Therapeutics director George Pavlov bought 25,000 shares of Voting Common Stock in open-market transactions. The purchases occurred on February 18, 19, and 20, 2026, at weighted average prices of about $17.48, $17.57, and $17.86 per share, bringing his directly held stake to 25,000 shares.

MapLight Therapeutics director Robert C. Malenka reported an open‑market sale of 12,116 shares of Voting Common Stock to cover tax obligations tied to restricted stock unit settlements. The weighted average sale price was $18.21 per share, with individual trades ranging from $18.00 to $18.59.

After this transaction, he held 339,254 shares directly and 31,672 shares indirectly through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power. Shares retained by him remain subject to a 180‑day lock‑up following the October 26, 2025 final prospectus for the company’s initial public offering.

MapLight Therapeutics director Timothy John Garnett reported an open‑market purchase of Voting Common Stock on February 10, 2026. Through the Timothy J Garnett Revocable Trust, he bought 14,124 shares at a weighted average price of $17.89 per share, with individual trades between $17.76 and $17.90. Following this transaction, the trust holds 14,124 shares indirectly for him, and he also holds 49,525 shares directly.

MapLight Therapeutics director Robert C. Malenka sold shares of voting common stock mainly to cover taxes tied to equity awards. On February 10, 2026 he sold 6,622 shares at a weighted average price of $18.12, and on February 11, 2026 he sold 241 shares at $18.00.

According to the footnotes, these sales were made to satisfy tax obligations upon settlement of restricted stock units. After the transactions, he directly owned 351,370 shares of voting common stock and indirectly held 31,672 shares through the Robert C. Malenka Living Trust, where he serves as sole trustee with voting and dispositive power.

The remaining securities are still subject to a lock-up agreement related to MapLight Therapeutics’ initial public offering, under which he agreed, with certain exceptions, not to sell or transfer shares for 180 days following the final prospectus dated October 26, 2025.

MapLight Therapeutics executive Jonathan Gillis received new equity awards in the form of stock options and restricted stock units (RSUs). On February 5, 2026, he was granted 24,455 employee stock options to buy voting common stock and 6,020 RSUs of voting common stock.

The RSUs vest over time, with one-quarter vesting on January 1, 2027 and the remainder vesting in equal installments each April 1, July 1, October 1, and January 1 thereafter, subject to continued service. The options vest with one-quarter on February 5, 2027 and the rest in equal monthly installments, also contingent on continued service.

MapLight Therapeutics Chief Financial Officer Vishwas Setia reported new equity awards. On February 5, 2026, he acquired 7,730 shares of voting common stock at $0, described as a restricted stock unit (RSU) award. One quarter of these RSUs will vest on January 1, 2027, with the remainder vesting in equal installments on each April 1, July 1, October 1 and January 1 thereafter, contingent on continued service.

Setia was also granted an employee stock option for 31,395 shares of voting common stock at an exercise price of $15.7 per share, expiring on February 4, 2036. One quarter of the option will vest on February 5, 2027, with the balance vesting monthly in equal installments, also subject to continued service. Following these awards, he directly holds 395,549 shares of voting common stock and 31,395 stock options.